高剂量附子理中汤联合化疗对中晚期结直肠癌的疗效分析  

Analysis of the Efficacy of High-Dose Fuzi Lizhong Decoction Combined with Chemotherapy on Middle and Advanced Colorectal Cancer

作　　者：张丽娜[1] 林秀[2] 李文娟 宾颜英 潘献彬 ZHANG Li-na;LIN Xiu;LI Wen-juan;BING Yan-ying;PAN Xian-bin(Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine,Nanning 530012,China;Hospital of Guilin University of Technology,Guilin 541004,China;Hospital of Guangxi Normal University,Guilin 541004,China)

机构地区：[1]广西中医药大学附属瑞康医院,南宁530012 [2]桂林理工大学医院,桂林541004 [3]广西师范大学医院,桂林541004

出　　处：《中国合理用药探索》2025年第1期40-46,共7页Chinese Journal of Rational Drug Use

基　　金：广西空间信息与测绘重点实验室主任开放基金项目(19-185-10-04)。

摘　　要：目的:探讨高剂量附子理中汤联合化疗对中晚期结直肠癌患者的临床疗效及安全性。方法:选取2020年1月~2022年6月期间于某院治疗100例结直肠癌患者作为研究对象,采用简单随机分组分为对照组和观察组,每组50例。两组患者均给予相同的CapeOX化疗方案,对照组患者加用低剂量附子理中汤,观察组患者加用高剂量附子理中汤,两组均治疗6周。比较两组患者心功能[乳酸脱氢酶(LDH)、肌酸激酶同工酶(CK-MB)和肌酸激酶(CK)]、肝功能[谷丙转氨酶(ALT)、谷草转氨酶(AST)]、肾功能[肌酐(Cr)、血尿素氮(BUN)]、临床疗效、中医证候疗效及不良反应发生情况。结果:两组患者治疗前后LDH、CK-MB、CK、ALT、AST、Cr和BUN水平比较均无统计学差异(P>0.05)。观察组患者客观缓解率(80.00%)高于对照组(56.00%,P<0.05),疾病控制率(96.00%)高于对照组(88.00%,P<0.05);中医证候疗效(90.00%)高于对照组(66.00%,P<0.05);白细胞减少、血小板减少、恶心呕吐的发生率均低于对照组(P<0.05)。结论:高剂量附子理中汤联合化疗可提高结直肠癌患者的临床疗效,减轻化疗不良反应,且未发生心肝肾功能损害。Objective:To explore the clinical efficacy and safety of high-dose Fuzi Lizhong decoction in combination with chemotherapy in the treatment of patients with middle and advanced colorectal cancer.Methods:A total of 100 patients diagnosed with colorectal cancer treated in a hospital from January 2020 to June 2022 were selected and assigned to the control group and the observation group by simple random grouping,with 50 patients in each group.Both groups were given the same CapeOX chemotherapy regimen.The control group was given low-dose Fuzi Lizhong decoction,while the observation group was given high-dose Fuzi Lizhong decoction.Both groups were treated for 6 weeks.Cardiac function[lactate dehydrogenase(LDH),creatine kinase isoenzyme(CK-MB)and creatine kinase(CK)],liver function[alanine aminotransferase(ALT),aspartate aminotransferase(AST)],renal function[creatinine(Cr),blood urea nitrogen(BUN)],clinical efficacy,traditional Chinese medicine(TCM)syndrome efficacy and incidence of adverse reactions were compared between the two groups.Results:No statistically significant differences in the levels of LDH,CK-MB,CK,ALT,AST,Cr and BUN were observed between the two groups before and after treatment(P>0.05).The objective remission rate of observation group(80.00%)was higher than that of control group(56.00%,P<0.05),and the disease control rate(96.00%)was higher than that of control group(88.00%,P<0.05).The efficacy of TCM syndrome in the observation group(90.00%)was significantly higher than that in the control group(66.00%,P<0.05).The incidence of leukopenia,thrombocytopenia,nausea and vomiting in the observation group was significantly lower than that in the control group(P<0.05).Conclusion:High-dose Fuzi Lizhong decoction combined with chemotherapy can enhance the clinical efficacy and reduce the incidence of chemotherapy-related adverse reactions,and no damage to the heart,liver and kidney function.

关 键 词：中晚期结直肠癌 高剂量附子理中汤 化疗 临床疗效 不良反应 

分 类 号：R735.3[医药卫生—肿瘤]